<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04247815</url>
  </required_header>
  <id_info>
    <org_study_id>ATI-450-RA-201</org_study_id>
    <nct_id>NCT04247815</nct_id>
  </id_info>
  <brief_title>Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA</brief_title>
  <official_title>A Phase 2a, Randomized, Investigator and Patient-blind, Sponsor-unblinded, Parallel Group, Placebo-controlled Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aclaris Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aclaris Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 study to investigate the safety, tolerability, PK, and PD of ATI-450 plus&#xD;
      methotrexate versus methotrexate alone in patients with moderate to severe RA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, randomized, investigator and patient-blind, sponsor-unblinded, parallel&#xD;
      group, placebo-controlled study to investigate the safety, tolerability, PK, and PD of&#xD;
      ATI-450 plus methotrexate versus methotrexate alone in patients with moderate to severe RA&#xD;
      with inadequate response to methotrexate. All subjects will be required to complete a safety&#xD;
      follow up visit 30 days post last study medication administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2020</start_date>
  <completion_date type="Actual">February 4, 2021</completion_date>
  <primary_completion_date type="Actual">February 4, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, investigator and patient-blind, sponsor-unblinded, parallel group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The blinded placebo drug is packaged to match the active study drug and will be stored under the same conditions.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure is the determination of the safety and tolerability of ATI-450 plus Methotrexate in patients with moderate to severe rheumatoid arthritis: Adverse Events (AEs)</measure>
    <time_frame>114 days</time_frame>
    <description>Adverse Events (AEs) will be coded with the Medical Dictionary for Regulatory Activities (MedDRA). AEs will be presented by system organ class and preferred term in frequency tables.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in high sensitivity C-reactive protein (hsCRP) levels</measure>
    <time_frame>Baseline through Day 114</time_frame>
    <description>Median percent change from baseline in hsCRP over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Disease Activity Score</measure>
    <time_frame>Baseline through Day 114</time_frame>
    <description>Mean change from baseline in Disease Activity Score using DAS28-CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Hand-Wrist Assessments</measure>
    <time_frame>Baseline through Day 84</time_frame>
    <description>Mean change from baseline in RAMRIS Hand-Wrist assessment of synovitis or osteitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with American College of Rheumatology (ACR) 20/50/70</measure>
    <time_frame>Baseline through Day 114</time_frame>
    <description>ACR20/50/70 will be calculated at each treatment visit and the proportion of subjects with a 20%, 50% and 70% improvement will be tabulated at each scheduled visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>ATI-450 plus Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATI-450 50mg oral tablet BID with a stable weekly dose of Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus Methotrexate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral tablet BID with a stable weekly dose of Methotrexate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATI-450</intervention_name>
    <description>Oral, small molecule MK2 inhibitor</description>
    <arm_group_label>ATI-450 plus Methotrexate</arm_group_label>
    <other_name>CDD-450</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo tablet manufactured to match ATI-450 in appearance</description>
    <arm_group_label>Placebo plus Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>7.5 mg to 25 mg weekly</description>
    <arm_group_label>ATI-450 plus Methotrexate</arm_group_label>
    <arm_group_label>Placebo plus Methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of adult-onset RA as defined by the 2010 American College of&#xD;
             Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria.&#xD;
&#xD;
          -  DAS28-CRP ≥3.2 defined as moderate to high disease activity.&#xD;
&#xD;
          -  Have moderately to severely active RA defined by at least 4/28 tender and 4/28 swollen&#xD;
             joints.&#xD;
&#xD;
          -  hsCRP ≥5 mg/L at screening.&#xD;
&#xD;
          -  Patients must have definitive intra-articular synovitis or osteitis defined as a score&#xD;
             of 1 or greater on a Hand-Wrist MRI as assessed by central imaging reader (using&#xD;
             RAMRIS).&#xD;
&#xD;
          -  On a stable MTX dose and a stable dose of folic or folinic acid prior to the screening&#xD;
             visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has a current acute or chronic immunoinflammatory disease other than RA which&#xD;
             may impact the course or assessment of RA.&#xD;
&#xD;
          -  Patient has an uncontrolled non-immunoinflammatory disease that may place the patient&#xD;
             at increased risk during the study or impact the interpretation of results.&#xD;
&#xD;
          -  History or evidence of active or latent tuberculosis.&#xD;
&#xD;
          -  Active infection requiring treatment with antibiotics.&#xD;
&#xD;
          -  Blood pressure levels (in supine position after at least 5 minutes rest): &lt;90 mmHg or&#xD;
             &gt;140 mmHg for systolic blood pressure or &lt;40 mmHg or &gt;90 mmHg for diastolic blood&#xD;
             pressure.&#xD;
&#xD;
          -  Are currently receiving corticosteroids at doses greater than 10 mg per day of&#xD;
             prednisone (or equivalent) or have been receiving an unstable dosing regimen of&#xD;
             corticosteroids within 2 weeks of the screening visit.&#xD;
&#xD;
          -  Have started treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or have&#xD;
             been receiving an unstable dosing regimen of NSAIDs within 2 weeks of the screening&#xD;
             visit.&#xD;
&#xD;
          -  Patients with history of stroke.&#xD;
&#xD;
          -  Any joint procedure in the past 90 days prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Gordon</last_name>
    <role>Study Director</role>
    <affiliation>Aclaris Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aclaris Investigational Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aclaris Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aclaris Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aclaris Investigational Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aclaris Investigational Site</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arthritis</keyword>
  <keyword>Rheumatoid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

